IPO Year:
Exchange: NASDAQ
SCHEDULE 13G - Whitehawk Therapeutics, Inc. (0001422142) (Subject)
10-Q - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
DEFA14A - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
DEF 14A - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
424B5 - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
EFFECT - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
S-3 - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
8-K/A - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
MORRISTOWN, N.J., May 8, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, today announced financial results for the first quarter ended March 31, 2025, and provided recent corporate progress. "By uniting novel approaches to tumor targeting with next wave technologies, our goal at Whitehawk Therapeutics is to efficiently deliver improved ADC therapies for patients with difficult-to-treat cancers. In the first quarter of 2025, we made meaningful progress in advancing our portfolio toward the clinic and remain on track to bring all t